Objective To study the efficacy and safety of somatostatin combined with omeprazole in the treatment of senile patients with severe acute pancreatitis (SAP).Methods A total of 82 patients over the age of 82 with SAP were randomly divided into a control group and an experiment group (n =41, respectively). The control group received conventional treatment and additionally administered with 40-mg omeprazole every day. On the basis of this, the experiment group was administered with 3-mg somatostatin. After one-week treatment, the clinical effect between the two groups was compared and the recovery time and complications were recorded. control group and an experiment group (n =41, respectively). The control group received conventional treatment and additionally administered with 40-mg omeprazole every day. On the basis of this, the experiment group was administered with 3-mg somatostatin. After one-week treatment, the clinical effect between the two groups was compared and the recovery time and complications were recorded.Results After the treatment, the total efficiency in the experiment group (95.12%) was significantly higher than that in the control group (80.49%) (P < 0.05); the hospitalization duration, intestinal function recovery time, abdominal pain relief time, recovery time of blood amylase and that of urine amylase and other indicators in the experiment group were shorter than those in the control group (P < 0.05), while there was no significant difference in complications between the two groups (P > 0.05).Conclusion On the basis of conventional treatment and somatostatin treatment, the addition of omeprazole can significantly improve the clinical effect on senile patients with SAP and shorten the recovery time of patients without significant increase in the incidence of complications, so it is worthy of clinical application.
国家科技期刊平台
NSTL
维普
万方数据
